Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics / Hospital laboratory routine molecular infectious-disease testing

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Hospital laboratory routine molecular infectious-disease testing

Molecular assays (respiratory, GI, bloodstream, meningitis panels and single-target PCR) run in hospital and clinical laboratories to support routine inpatient and outpatient diagnosis of common infectious disease. Job to be done: deliver a validated, high-throughput, low-cost-per-result molecular answer for patients already in the care pathway. Excludes rapid/point-of-care results returned in under ~30 minutes (separate niche) and complex genomic interpretation work (separate niche).

Market size
$8.8B
$8.8B ($6.9B–$10.7B) · 2025 · Triangulated
Growth
+7.0%
$12.3B by 2030
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
7 sources · Triangulated
Level
Niche
Segmented by
Customer type
Buyers
Hospital and clinical laboratories (public and private hospital systems, integrated lab networks)
Buying centre
Centralised hospital laboratory procurement and capital equipment committee, with input from microbiology/lab medicine leadership, infection control, and hospital finance; multi-year framework agreements with reagent rental or instrument-placement terms.
Buying triggers
  • Respiratory and sepsis season volumes and outbreak-driven testing demand
  • Replacement or expansion of installed PCR/automated molecular platforms
  • Hospital cost-reduction and lab-consolidation programmes
  • Reimbursement and tender cycles for panel-based syndromic testing
Pains
  • Per-test cost and consumable spend pressure under fixed DRG/reimbursement budgets
  • Instrument capital spending caution and instrument-placement terms that lock in reagent volumes
  • Fragmented legacy platform estates and open-reagent versus closed-cartridge trade-offs
  • Menu breadth needed to cover respiratory, GI and bloodstream panels without excessive capital
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability—
Growth—

How this was sized

$8.8B ($6.9B–$10.7B) · 2025 · Triangulated

Pool triangulation: published 2025 clinical diagnostics revenue estimates of USD 81.74B [10], USD 86.5B [9], USD 92.37B [1], USD 110.85B [8], USD 115.4B [6] and USD 118.60B [3] give a mid-point of ~USD 100B. Molecular and specialised diagnostics assumed at 22% of that pool (immunodiagnostics alone is 28.2% of laboratory diagnostics [8], with molecular the next-largest technology block) = USD 22.0B submarket. Routine infectious-disease molecular assumed 40% of the submarket = USD 8.8B (range 6.9-10.7B). Forecast: 8,800 x 1.07^5 = USD 12,340M in 2030; 7.0% CAGR sits above the 4.78% clinical diagnostics CAGR [1] and near the 6.6% diagnostic tests CAGR [3], reflecting molecular mix gain. Low confidence: both the 22% share and the 40% allocation are assumptions, not published figures.

Alongside it in Molecular and specialised diagnostics

// Sell into Hospital laboratory routine molecular infectious-disease testing

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.